Hürthle Cell Carcinoma of the Thyroid Gland: Systematic Review and Meta-analysis

Author(s):  
Andrés Coca-Pelaz ◽  
Juan P. Rodrigo ◽  
Jatin P. Shah ◽  
Alvaro Sanabria ◽  
Abir Al Ghuzlan ◽  
...  
Thyroid ◽  
2012 ◽  
pp. 120301085144008
Author(s):  
Justin Bishop ◽  
Gaosong Wu ◽  
Ralph P. Tufano ◽  
William H Westra

2015 ◽  
Vol 49 (1) ◽  
pp. 26-31 ◽  
Author(s):  
Nevena Ristevska ◽  
Sinisa Stojanoski ◽  
Daniela Pop Gjorceva

Abstract Background. Hürthle cell neoplasms could be benign (Hürthle cell adenoma) or malignant (Hürthle cell carcinoma). Hürthle cell carcinoma is a rare tumour, representing 5% of all differentiated thyroid carcinomas. The cytological evaluation of Hürthle cell neoplasms by fine needle aspiration biopsy (FNAB) is complicated because of the presence of Hürthle cells in both Hürthle cell adenoma and Hürthle cell carcinoma. Thus, the preoperative distinction between these two entities is very difficult and possible only with pathohistological findings of the removed tumour. Case report. A 57-year old female patient was admitted at our Department, for investigation of nodular thyroid gland. She was euthyroid and FNAB of the nodules in both thyroid lobes were consistent of Hürthle cell adenoma with cellular atypias. After thyroidectomy the histopathology revealed Hürthle cell adenoma with high cellular content and discrete cellular atypias in the left lobe and follicular thyroid adenoma without cellular atypias in the right lobe. One year after substitution therapy, a palpable tumour on the left side of the remnant tissue was found, significantly growing with time, presented as hot nodule on 99mTc-sestamibi scan and conclusive with Hürthle cell adenoma with marked cellularity on FNAB. Tumorectomy was performed and well-differentiated Hürthle cell carcinoma detected. The patient received ablative dose of 100 mCi 131I. No signs of metastatic disease are present up to date. Conclusions. The differences between Hürthle cell adenomas and Hürthle cell carcinomas could be clearly made only by histopathological evaluation. Patients with cytological diagnosis of Hürthle cell neoplasms should proceed to total thyroidectomy, especially if tumour size is > 1cm, FNAB findings comprise cellular atypias and/or multiple bilateral nodules are detected in the thyroid gland.


2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e13048-e13048
Author(s):  
David Allen ◽  
Ross Wanner ◽  
Sean McDermott ◽  
Jihad Aljabban ◽  
Saad Syed ◽  
...  

e13048 Background: Hurthle Cell Carcinoma (HCC), a variant of follicular thyroid carcinoma, is a rare form of thyroid cancer. Though it accounts for 3-10% of thyroid cancer cases, very little is known about its pathogenesis. While HCC holds good survival rates, it is still vital to understand the pathogenesis of HCC in order to further optimize treatment protocols. Methods: We tagged 46 HCC samples and 90 healthy thyroid samples as a control. Gene signatures were analyzed in Ingenuity Pathway Analysis, using statistical significance p < 0.05 and absolute log ratio > 0.5 between disease and controls. Methods: Search Tag Analyze Resource was employed to conduct meta-analysis using the National Center for Biotechnologys Gene Expression Omnibus to define HCC pathogenesis. Results: Hepatic fibrosis, hepatic stellate cell activation and retinoic acid receptor (RAR) activation were the top canonical activators associated with HCC. Of the molecules involved, Defensin Beta 1 (DEFB1), Lipocalin-2 (LCN2), Aldehyde Dehydrogenase 1 Family Member A3 (ALDH1A3), and CDC28 Protein Kinase Regulatory Subunit 2 (CKS2) had the highest associations with HCC. The most down-regulated molecules were Hemoglobin Subunit Beta (HBB), Hemoglobin Subunit Alpha 1 and 2 (HBA1/HBA2), Cellular Retinoic Acid Binding Protein 1 (CRABP1), and BH3-Interacting Domain-Containing Protein 3 (HRK). Conclusions: These results suggest that there are a variety of factors at play regarding the development of HCC. Defensins are peptides made by neutrophils, however DEFB1 is specifically known for its ability to resist bacterial growth on epithelial surfaces, playing a major role in innate immunity. LCN2 is also known for resisting growth on surfaces and does so by sequestering iron-containing siderophores, thus effectively stopping growth of microorganisms. Additionally, ALDH1A3 and CRABP1 are associated with RAR activation. While the exact pathogenesis of HCC is not well known yet, we demonstrate that the two most up-regulated factors in HCC are strongly involved in innate immunity. This suggests that the dysfunction of innate immunity may play a vital role in the neoplastic pathogenesis of HCC.


Cancer ◽  
2006 ◽  
Vol 106 (8) ◽  
pp. 1669-1676 ◽  
Author(s):  
Ronald A. Ghossein ◽  
David H. Hiltzik ◽  
Diane L. Carlson ◽  
Snehal Patel ◽  
Ashok Shaha ◽  
...  

Cancer ◽  
1986 ◽  
Vol 57 (8) ◽  
pp. 1613-1617 ◽  
Author(s):  
Gady Har-el ◽  
Tuvia Hadar ◽  
Karl Segal ◽  
Rudy Levy ◽  
Jack Sidi

Thyroid ◽  
2012 ◽  
Vol 22 (7) ◽  
pp. 690-694 ◽  
Author(s):  
Justin A. Bishop ◽  
Gaosong Wu ◽  
Ralph P. Tufano ◽  
William H. Westra

Sign in / Sign up

Export Citation Format

Share Document